Our mission is to become a worldwide reference for education in the field for all professionals involved in the process to disseminate knowledge & skills of Acute Cardiovascular Care.
Our mission is to promote excellence in clinical diagnosis, research, technical development, and education in cardiovascular imaging in Europe.
Our mission is to promote excellence in research, practice, education and policy in cardiovascular health, primary and secondary prevention.
Our mission is to reduce the burden of cardiovascular disease in Europe through percutaneous cardiovascular interventions.
Our mission is to improve the quality of life of the population by reducing the impact of cardiac rhythm disturbances and reduce sudden cardiac death.
Our mission is to improve quality of life and longevity, through better prevention, diagnosis and treatment of heart failure, including the establishment of networks for its management, education and research.
The ESC Working Groups' goal is to stimulate and disseminate scientific knowledge in different fields of cardiology.
The ESC Councils' goal is to share knowledge among medical professionals practising in specific cardiology domains.
OUR MISSION: TO REDUCE THE BURDEN OF CARDIOVASCULAR DISEASE
Anthracyclines are a cornerstone of oncology treatment but the more cycles needed to fight cancer, the more cardiotoxic side effects the patient will have. Austrian study shows that the cardiotoxicity can be reduced with liposomal encapsulation. Cardiac monitoring of all patients receiving anthracyclines is essential to detect early deterioration of the heart and give preventive treatment
Vienna, Austria – 05 December 2014: Austrian researchers have shown that a new technique which wraps chemotherapy drugs in a fatty cover (called a liposome) reduces heart damage, in a study presented today at EuroEcho-Imaging 2014 by Professor Jutta Bergler-Klein and Professor Mariann Gyöngyösi from the Medical University of Vienna, Austria.EuroEcho-Imaging is the annual meeting of the European Association of Cardiovascular Imaging (EACVI), a branch of the European Society of Cardiology (ESC), and is held 3-6 December in Vienna.Professor Bergler-Klein said:
“Cancer survival has greatly improved, especially in breast cancer and lymphomas. But many chemotherapies, in particular anthracyclines, cause cardiac side effects that can lead to cardiomyopathy and severe heart failure. This is a frequent problem and when we see these patients it’s terrible, for example a breast cancer patient who is developing heart failure. Of course we cannot ask oncologists to stop the chemotherapy because without it the patient will die.”
“Cardiotoxicity can occur acutely or up to 30 years after chemotherapy and is the second most common cause of death in cancer patients, after secondary malignancy in childhood cancer survivors. Risk increases with more chemotherapy or when radiation is also given. That is why it’s so important to use a regimen that has as few cardiac side effects as possible.”
Professor Bergler-Klein continued:
“Liposomal encapsulation is a new technique which wraps the chemotherapy drug in a fatty cover called a liposome. More of the drug reaches the cancer cells because there is less degradation and there are fewer side effects on healthy cells because the fat cover acts as a barrier. The drug stays in the bloodstream longer, allowing higher cumulative doses to be given. We tested whether non-pegylated liposome encapsulation of the anthracycline doxorubicin (called Myocet) could decrease its cardiotoxicity compared to conventional doxorubicin or epirubicin, another anthracycline.”
The study included 24 pigs that were randomised to receive the human dose-equivalent of either Myocet, conventional doxorubicin, or epirubicin in 3 cycles. Cardiac function was assessed by echocardiography and magnetic resonance imaging (MRI) at baseline and follow up (after about 3 months). Laboratory follow up included haematology, renal function, and measurement of the cardiac enzymes troponin and BNP. The epirubicin group was excluded from the final analyses because of low survival levels.Professor Bergler-Klein said:
“The dose, imaging methodology and blood parameters simulate the monitoring that patients on this treatment would receive and produces valuable translational data.”
The researchers found that the group receiving Myocet had better diastolic and systolic function in the left and right ventricles, compared to conventional doxorubicin. The Myocet group also had less fibrosis development in the myocardium as shown by MRI and histology staining.Professor Bergler-Klein said:
“Our study shows that doxorubicin encapsulated in a liposome had fewer cardiac side effects than doxorubicin given in the conventional way. We did find cardiac toxicity in the Myocet group as well, despite the fact that the pigs were young, healthy, and received anthracyclines for only a short period. This emphasises how important it is for all cancer patients taking anthracyclines to receive cardiac monitoring using echocardiography and biomarkers, and MRI where indicated.”
“Many patients who recover after chemotherapy have asymptomatic heart damage which can become symptomatic as they get older. When heart problems are picked up early patients can be given preventive treatment including ACE inhibitors, angiotensin receptor blockers or beta blockers to prevent the progression to overt heart failure.”
The researchers are conducting gene expression profiling on the histology samples which may explain the better outcome and cardiac function after Myocet therapy. They have found differences in the expression of the genes that control energy use and the metabolic state, with better regulation in the Myocet group.Professor Bergler-Klein concluded:
“Anthracyclines are a cornerstone of oncology treatment but the more cycles needed to fight cancer, the more cardiotoxic side effects the patient will have. We have shown that the cardiotoxicity can be reduced with liposomal encapsulation. Cardiac monitoring of all patients receiving anthracyclines is essential to detect early deterioration of the heart and give preventive treatment.”
ESC references and projects in cardiac oncologyExpert consensus for multi-modality imaging evaluation of cardiovascular complications of radiotherapy in adults: a report from the European Association of Cardiovascular Imaging and the American Society of Echocardiography. Eur Heart J Cardiovasc Imaging. 2013 Aug;14(8):721-40. doi: 10.1093/ehjci/jet123. Expert consensus for multimodality imaging evaluation of adult patients during and after cancer therapy: a report from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. Eur Heart J Cardiovasc Imaging. 2014 Oct;15(10):1063-93. doi: 10.1093/ehjci/jeu192.The ESC/EACVI’s Cardiac Oncology Toxicity Registry was launched in September to collect data on practices for identifying and treating cardiotoxicity of breast cancer drugs.
About the European Association of Cardiovascular Imaging (EACVI)The European Society of Cardiology (ESC) represents more than 80 000 cardiology professionals across Europe and the Mediterranean. The European Association of Cardiovascular Imaging (formerly EAE) is a registered branch of the ESC. Its aim is to promote excellence in clinical diagnosis, research, technical development, and education in cardiovascular ultrasound and other imaging modalities in Europe.Information for journalists attending EuroEcho-Imaging 2014EuroEcho-Imaging 2014 takes place during 3-6 December in Vienna, Austria, at the Reed Messe Wien GmbH congress centre. The full scientific programme is available here
© 2017 European Society of Cardiology. All rights reserved